Cyclical olefins and polyolefins valuation. Capitalize a through-cycle adjusted EBITDA at a chemicals EV/EBITDA multiple, subtract net debt, and divide by diluted shares. Do not annualize Q2 2026's $2.13B adjusted EBITDA: that print was a Middle East supply-shock spike (23% margin, record $0.30/lb April PE hike) that began reversing in June, with Q3 operating rates guided down for Clinton/Lake Charles turnarounds. This is not an INTC/MU FCF-yield clone and not a bank P/TBV: 2025 FCF collapsed to $0.38B and LYB's earnings power is spread- and utilization-driven. Both public Modeledge LYB models already use through-cycle EV/EBITDA; this notebook keeps that basis, uses a live current_price input, and does not treat unobservable spread indices as if they were contract prices.
as of 2026-08-25
| FY2026E | |
|---|---|
| Q2 2026 adjusted EBITDA (do not annualize) | $2.13 |
| Q2 annualized (illustrative only) | $8.51 |
| H1 2026 annualized (includes spike) | $5.48 |
| Through-cycle adjusted EBITDA | $4.50 |
| EV / EBITDA multiple | 7.0 |
| Implied enterprise value | $31.50 |
| Gross debt | $12.91 |
| Cash and liquid investments | $2.64 |
| Net debt | $10.27 |
| Implied equity value | $21.23 |
| Implied through-cycle FCF | $2.48 |
| Fair value per share | $65.73 |
Built with Modeledge MCP
Connect your MCP client to research filings and earnings calls, then build a living financial model like this one.